drugset / Trial / NCT00638833
Memantine Therapy for Multiple Sclerosis
Phase 2
Terminated
20 enrolled
Clinica Universidad de Navarra, Universidad de Navarra
H. Lundbeck A/S · collab
RandomizedCrossoverDouble-blindTreatment
Summary
To assess the efficacy of Memantine in improving the cognitive impairment in patients with Multiple Sclerosis (MS)
Timeline
- Start
- 2007-09
- Primary completion
- 2008-03
- Completion
- 2008-03
Publications
- Background Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F, Garcea O, Villoslada P. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler. 2006 Apr;12(2):187-95. doi: 10.1191/1352458506ms1258oa.
- Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009 May 12;72(19):1630-3. doi: 10.1212/01.wnl.0000342388.73185.80. Epub 2008 Dec 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Memantine | Unknown | 30 mg | — |